The Hidden Architecture of Drug Shortages: Why Inventory Economics Determine Patient Access

When a pharmacist tells a patient that their medication is unavailable, the conversation rarely turns to First-Expiry-First-Out (FEFO) compliance gaps, working capital constraints, or the financial mechanics of inventory sequencing. Yet it is precisely these invisible financial structures, not manufacturing breakdowns or regulatory shortcomings alone, that determine whether critical medicines reach patients on time, at affordable prices, and in sufficient quantities.

As a finance professional who has spent over nine years managing pharmaceutical inventory economics across a multi-billion-dollar North American generics operation, I have observed firsthand how the financial architecture underlying drug supply chains remains one of the least understood, and most consequential, drivers of patient access. This article attempts to make that architecture visible.

What Is The Scale of US Drug Shortages?

The United States is facing a drug shortage crisis of historic proportions. According to the American Society of Health-System Pharmacists (ASHP), active drug shortages reached an all-time high of 323 in the first quarter of 2024, the highest level recorded since tracking began in 2001. As of early 2025, over 270 medications remained in active shortage, with three-quarters of all active shortages having originated in 2022 or later.¹

The consequences for patients are severe and well-documented. In a 2023 ASHP survey of more than 1,000 hospital pharmacists, 99% reported experiencing drug shortages, with 32% characterizing the situation as "critical", meaning they were actively rationing, delaying, or canceling treatments or procedures. More than half reported facing critical shortages of chemotherapy drugs directly impacting cancer patient care. An earlier analysis estimated that the annual labor cost of drug shortages to US hospitals alone is $359 million.²

Critically, these shortages are not short-term disruptions. According to ASHP data, 50% of active drug shortages in the United States persist for two or more years.³ The HHS Office of the Assistant Secretary for Planning and Evaluation estimates that each shortage affects approximately 500,000 people, with more than 30% of those impacted falling between the ages of 65 and 85.⁴

These statistics describe a public health emergency. But they do not explain it. To understand why drug shortages occur, and persist, one must look beneath the clinical and regulatory surface to the financial architecture that governs pharmaceutical inventory decisions.

The Disconnect Between Public Narrative and Financial Reality

Public discourse on drug shortages tends to center on manufacturing disruptions, FDA warning letters, and geopolitical supply dependencies. These are real and important factors. According to an HHS/ASPE analysis of drug shortages between 2018 and 2023, over twice as many generic drug shortages occurred as brand drug shortages, with 1,391 generic shortage events compared to 600 brand shortage events, reflecting the particular vulnerability of the generic supply chain.⁵

The same analysis found that as of August 2024, only 24% of active pharmaceutical ingredient (API) manufacturing facilities for US-marketed drugs were located in the United States.⁵ The bulk of US pharmaceutical imports come from just two countries. In 2024, the United States imported over 828,000 metric tons of pharmaceuticals, seven times the volume imported in 2000, with China and India together supplying an estimated 70–80% of the total US generic drug supply, creates a supply chain that is simultaneously vast in scale and fragile in structure.⁶ A single drug may pass through five to seven countries between raw material extraction and a patient's hands.

Yet geopolitical concentration alone does not explain why shortages emerge, persist, and disproportionately affect the most vulnerable patients. A critical and underappreciated dimension of the solution lies in financial expertise: the inventory economics that governs how pharmaceutical companies decide how much medicine to hold, where to hold it, and how to sequence its distribution represent one of the most powerful, and most underutilized, levers available to address the shortage crisis.

This is the central insight that shapes this article: sophisticated financial management in pharmaceutical supply chains is not merely a business function, it is a patient access function. When financial leaders apply rigorous inventory analytics, working capital optimization, and logistics cost management with patient access as a primary objective alongside financial performance, the results are measurable in both dollars and lives. The challenge is that this expertise is unevenly distributed across industry, and where it is absent or underdeveloped, shortages are more likely to emerge, deepen, and persist.

Why Do Margins Create Vulnerability?

To understand drug shortage economics, one must first understand the financial reality of generic drug manufacturing. Generic drugs are, by design, a commoditized business built on a powerful social compact: manufacturers accept thin margins in exchange for the volume and market access that comes with producing medicines that 9 in 10 Americans depend on. According to the Association for Accessible Medicines, generic and biosimilar medicines saved the US healthcare system $467 billion in 2024 alone.⁷ That affordability is the direct result of disciplined financial management, and it is precisely why financial expertise in this sector carries such outsized public health significance.

Price erosion is structural: when multiple manufacturers compete for the same molecule, prices decline rapidly and profit margins compress to levels where inventory management decisions become existential. In this environment, every dollar of inventory represents a financial decision with compounding implications. Excess inventory ties up working capital, generates carrying costs, and, critically, creates exposure to expiry losses that can devastate margins on low-price generic products.

This financial pressure drives pharmaceutical companies toward lean inventory strategies, holding the minimum stock necessary to meet expected demand while minimizing working capital exposure. Research published in the Journal of Supply Chain Management has documented how COVID-19 created "further stress on already-lean drug supply chains," exposing the systemic fragility of just-in-time inventory models in pharmaceutical manufacturing.⁸

In practice, lean inventory models create a system with almost no buffer against demand volatility, supply disruptions, or forecasting errors. When demand spikes unexpectedly, as occurred with generic antibiotics during the respiratory illness surge of 2022-2023, which drove significant price increases for amoxicillin and forced many physicians to switch to costlier alternatives, companies operating lean inventory models have no reserve to draw on, companies operating lean inventory models have no reserve to draw on.⁹ The shortage that patients experience is not solely the result of a factory shutting down. It is the result of models optimized for efficiency rather than resilience.

Why Does FEFO Compliance and Continuous Financial Monitoring Keep Medicines on Shelves?

One of the most powerful, and underutilized, tools for protecting drug availability is rigorous, finance-led monitoring of FEFO compliance. FEFO requires that products closest to expiration are shipped and dispensed first, protecting patient safety and preventing the inventory destruction that removes medicine from the supply chain. Research compiled by Management Sciences for Health, a leading global health organization supported by USAID, estimates that inadequate inventory control alone accounts for the loss of 4–9% of pharmaceuticals across supply systems globally.¹⁰ In commercial distribution environments processing hundreds of thousands of transactions monthly, even a 4% loss rate represents millions of dollars in destroyed inventory and thousands of units unavailable to patients. Every unit destroyed is a unit unavailable to a patient who needs it.

The critical insight is that FEFO compliance cannot be delegated to warehouse management systems and considered resolved. WMS platforms execute FEFO correctly at the individual transaction level, but they cannot audit themselves. Several failure modes operate silently below the transaction level and are only detectable through independent finance-led monitoring: new warehouse locations added operationally may not be configured within the WMS FEFO logic, leaving aging inventory invisible to expiry sequencing; many systems apply FEFO only to active pick locations, while passive reserve locations accumulate expiry risk undetected; when FEFO is intentionally overridden to fulfill a customer's request for longer-dated product, some systems anchor subsequent picks to the most recently dispensed batch rather than resetting to the true earliest-expiry lot, silently cascading a single override into a sustained sequencing error.

At the transaction volumes that characterize large pharmaceutical distribution operations, hundreds of thousands of order lines processed monthly across multiple locations and logistics partners, the probability that one or more of these failure modes will manifest is not theoretical. It is near-certain. No periodic manual audit will catch it in time. The only reliable safeguard is an independent finance-led system that operates parallel to the WMS: continuously reconciling dispensing patterns against inventory age profiles, auditing sales movement against shipped inventory composition, and flagging divergences between what the WMS reports and what expiry-informed financial planning requires. This system does not duplicate the WMS, it audits the WMS, ensuring its configuration is complete, its reset behavior is correct, and its outputs are consistent with keeping medicines moving to patients and losses off the income statement.

Why Is Financial Intelligence the First Line of Defense?

When a drug shortage emerges, supply chain pressures can intensify rapidly, but companies equipped with the right financial monitoring systems can identify the warning signs early enough to respond before patients are affected. This is where pharmaceutical financial intelligence moves from a back-office function to a frontline patient access tool.

The mechanism by which shortages deepen is well-documented in academic research. A study published in Management Science found that demand surges, driven by stockout aversion among buyers, significantly amplified supply constraints that manufacturers had the capacity to meet under normal ordering patterns.¹¹ When buyers anticipate continued disruption, order volumes increase well beyond immediate needs, creating a mismatch between actual patient demand and the supply chain signals manufacturers receive. The result is a self-reinforcing cycle: perceived scarcity drives over-ordering, over-ordering accelerates real scarcity, and patients bear the consequences.

Finance-led monitoring systems break this cycle by making the distortion visible before it becomes irreversible. In practice, this means maintaining continuous days-on-hand tracking at both the customer and wholesaler level, monitoring not just aggregate inventory positions but individual buyer behavior, so that when a customer suddenly orders three times their historical run rate, the anomaly is flagged immediately rather than discovered weeks later when inventory has already been depleted. It means running dynamic demand forecasts based on real customer order patterns rather than static historical averages, so that when order behavior shifts, the forecast shifts with it and inventory risk is recalculated in near real time.

Equally important is monitoring the external market with the same analytical rigor applied to demand. FDA warning letters, consent decrees, plant shutdowns, and regulatory holds affecting competitor manufacturers are early indicators of market-wide supply gaps that will manifest as patient-facing shortages weeks or months later. When a competitor receives an FDA warning letter that halts production, or when a natural disaster disrupts a rival's manufacturing facility, the patients who depend on that competitor's products do not simply stop needing their medication, they turn to whatever supply remains in the market. Finance teams that track these competitor-level disruptions systematically, cross-referencing market supply signals against their own inventory positions and production capacity, can identify at-risk molecules before the shortage becomes visible, and proactively scale inventory, accelerate procurement, and position supply to serve patients who would otherwise face a gap. This transforms financial intelligence from a defensive function into a patient access function: not merely protecting your own supply chain, but actively filling the gaps that competitor disruptions leave in the broader market.

When supply constraints do emerge despite these precautions, scenario modeling becomes the critical decision-support tool. By projecting inventory runway under different demand assumptions, base case, elevated demand, severe shortage, finance leaders can give commercial and supply chain teams the quantitative foundation they need to make rational allocation decisions: which customers to prioritize, which SKUs require immediate procurement intervention, and at what inventory level escalation to senior leadership is warranted. The ASHP 2023 survey documents what happens when these systems are absent: 85% of hospital pharmacists resorted to drug rationing, 97% switched to therapeutic alternatives, and more than 40% delayed or canceled treatments.² These are not inevitable outcomes of supply disruption.

The financial stakes are particularly high for smaller buyers, independent pharmacies, rural hospitals, community health centers, who serve the most vulnerable patient populations. HHS data shows that over 30% of shortage-affected patients are between 65 and 85 years old.⁴ Finance leaders who build allocation frameworks grounded in historical customer need rather than purchasing power alone ensure that constrained supply reaches the patients who depend on it most, making financial discipline a direct instrument of health equity.

How Does Logistics Economics Determine Drug Affordability and Availability?

A dimension of pharmaceutical supply chain economics that receives insufficient attention is the direct relationship between freight costs and drug prices. The COVID-19 pandemic made this relationship impossible to ignore. According to the Association for Accessible Medicines, transport costs for generic and biosimilar drug manufacturers increased by an average of 224% during the pandemic, with at least one manufacturer reporting a 413% increase in shipping expenses compared to pre-crisis levels.¹² For an industry where per-unit margins are measured in cents rather than dollars, cost increases of this magnitude are not operational inconveniences, they are existential threats to product economics, forcing companies to choose between absorbing losses, passing costs through to buyers, or reducing shipment volumes in ways that directly produce patient-facing shortages.

But freight cost management is not merely a crisis-response consideration, it is a permanent and structurally significant component of pharmaceutical cost architecture with two equally important implications: drug affordability and drug availability. On the affordability dimension, logistics costs represent a meaningful share of total landed cost in a supply chain where products travel thousands of miles between API manufacturers in Asia and patients in the United States. In the generic pharmaceutical market, where per-unit margins are already compressed by structural price competition, every dollar of unnecessary freight cost either erodes the economics that keep a product in production or is passed through to buyers as higher drug prices. Finance leaders who rigorously optimize freight expenditure are directly influencing what patients pay at the pharmacy counter.

The availability dimension is equally consequential and less widely understood. When freight costs rise sharply, whether due to a pandemic, a geopolitical disruption, a natural disaster affecting port operations, or a surge in global shipping demand, pharmaceutical companies face an immediate choice about shipment volumes. Products with the thinnest margins are the first candidates for reduced shipment frequency, delayed orders, or market exit. The result is not merely a cost problem, it is a supply problem. Medicines become unavailable not because manufacturing has failed but because the economics of moving them to market have deteriorated beyond what thin generic margins can absorb. Proactive freight cost management, securing capacity, optimizing shipping modes, and building logistics cost visibility into product economics before disruption strikes, is therefore as much a supply continuity strategy as it is a cost reduction strategy.

The modal analysis of air freight versus sea freight illustrates this clearly. Transitioning from air to sea freight extends lead times by three to five weeks, a change with cascading implications for inventory positioning, safety stock requirements, shelf life consumption, and working capital. A product that arrives by air in five days and reaches pharmacies with eleven months of remaining shelf life arrives by sea in thirty-five days with ten months of remaining shelf life. The financial model must account for increased inventory investment to buffer against longer replenishment cycles, shelf life risk associated with slower transit, and the demand forecasting precision required to avoid both stockouts and expiry losses. When this total landed cost analysis is conducted rigorously, weighing freight savings against inventory carrying costs, shelf life exposure, and supply continuity risk, sea freight optimization frequently generates material cost savings that can be passed directly through to buyers as lower drug prices. These are the kinds of financial decisions, invisible to patients and policymakers, that ultimately determine whether a medicine is affordable enough to remain accessible to the patients who need it.

Toward a Financial Architecture That Serves Patients

If drug shortages are partly a financial architecture problem, then solutions must address financial architecture alongside manufacturing capacity, regulatory oversight, and supply chain geography. The April 2025 GAO report on drug shortages explicitly recommended that HHS develop formal cross-agency collaboration mechanisms, recognizing that "fully addressing shortages will require working across FDA and its other agencies, and with others.”¹³ Financial policy reform is a necessary component of that broader collaboration.

Several structural reforms warrant serious consideration:

• Strategic inventory requirements tied to national security designations. For drugs designated as essential medicines or critical to national security, mandatory minimum inventory levels, enforced through financial penalties for non-compliance, would create a buffer against demand volatility and supply disruption. The cost of maintaining these strategic reserves should be reflected in drug pricing frameworks, particularly for government payer programs.
• Working capital incentives for inventory resilience. Tax treatment of pharmaceutical inventory currently creates incentives to minimize stock levels. Reorienting these incentives, through accelerated depreciation for strategic inventory, or tax credits for maintaining buffer stock in essential drug categories, would align financial decision-making with public health objectives without requiring direct regulatory intervention.
• FEFO compliance as a formally monitored quality metric. Current quality frameworks for pharmaceutical manufacturing focus heavily on production-side compliance. Extending formal FEFO compliance requirements to distribution and logistics operations, with clear financial accountability for violations, would reduce the preventable inventory losses that remove medicine from the supply chain before it reaches patients.
• Freight cost transparency in drug pricing negotiations. Payer negotiations for generic drug contracts rarely incorporate explicit treatment of logistics costs. Creating standard frameworks for freight cost passthrough, particularly during periods of logistics market disruption, would reduce the incentive to cut inventory as a way of managing cost shocks.
• AI-driven demand forecasting investment. The gap between actual patient demand and pharmaceutical company demand forecasts is a primary driver of inventory mismanagement. The USP 2024 Annual Drug Shortages Report identified economic factors, including demand forecasting failures, as primary underpinnings of persistent shortages.¹⁴ Investment in AI-based demand planning tools, with incentives for smaller generic manufacturers who cannot self-fund these capabilities, would reduce the forecasting errors that create both excess inventory and shortage conditions.

Drug shortages are headline events with hidden causes. When a hospital cannot obtain a critical antibiotic, or a cancer patient faces treatment delays because their chemotherapy drug is unavailable, the public conversation focuses on the visible, manufacturing failures, import dependencies, regulatory gaps. The invisible financial architecture that shapes inventory decisions, logistics economics, working capital allocation, and supply chain investment receives far less attention.

This invisibility has a cost. Until pharmaceutical financial management is recognized as a determinant of patient access, as consequential as manufacturing capacity or regulatory compliance, the structural drivers of drug shortages will remain unaddressed. The ASHP data showing that 50% of active shortages persist for two or more years is a signal that manufacturing and regulatory interventions alone are insufficient.³ Durable solutions require equal attention to the financial systems that govern how medicines are held, sequenced, and distributed, because it is at this layer of the supply chain where the difference between a shortage that resolves in weeks and one that persists for years is most often determined.

The medicines that reach patients are not simply the products of chemistry and manufacturing. They are the products of financial decisions made at every node of a complex, global supply chain. Understanding and reforming those financial decisions is not an accounting exercise. It is a public health imperative.

Amber Hussain Siddique is the director of finance at Dr. Reddy's Laboratories.

References

1. American Society of Health-System Pharmacists. "Drug Shortages Statistics." University of Utah Drug Information Service. ashp.org/drug-shortages/shortage-resources/drug-shortages-statistics.
2. American Society of Health-System Pharmacists. "Severity and Impact of Current Drug Shortages: ASHP Drug Shortage Survey Report, June/July 2023." news.ashp.org/-/media/assets/drug-shortages/docs/ASHP-2023-Drug-Shortages-Survey-Report.pdf.
3. American Society of Health-System Pharmacists. "2024 Drug Shortages Annual Report." University of Utah Drug Information Service. October 2024. ashp.org/drug-shortages/shortage-resources/drug-shortages-statistics.
4. Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. "Impact of Drug Shortages on Consumer Costs." May 2023. aspe.hhs.gov/reports/drug-shortages-impacts-consumer-costs.
5. McGeeney, J.D., McAden, E. and Sertkaya, A. "Analysis of Drug Shortages, 2018–2023." Eastern Research Group, Inc., prepared for the U.S. Department of Health and Human Services. January 2025. aspe.hhs.gov.
6. Coalition for a Prosperous America. "U.S. Dangerously Reliant on High-Risk Imported Drug Supply." May 2025. prosperousamerica.org/u-s-dangerously-reliant-on-high-risk-imported-drug-supply.
7. Association for Accessible Medicines. "2025 U.S. Generic & Biosimilar Medicines Savings Report." 2025. accessiblemeds.org/resources/reports/2025-savings-report.
8. Jacobson, S.H., et al. "Pharmaceutical supply chain reliability and effects on drug shortages." Journal of Supply Chain Management. May 2022. sciencedirect.com/science/article/abs/pii/S036083522200328X.
9. American Society of Health-System Pharmacists. "Drug Shortage Detail: Amoxicillin Oral Presentations." University of Utah Drug Information Service. Created Oct. 20, 2022; updated Dec. 9, 2025. ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=875.
10. Management Sciences for Health. MDS-3: Managing Access to Medicines and Health Technologies. Arlington, Va.: Management Sciences for Health, 2012. msh.org/resources/mds-3-managing-access-to-medicines-and-health-technologies.
11. Park, M., Carson, A.L., Fox, E.R. and Conti, R.M. "Stockpiling at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices." Management Science. 2024;70(10):6483–6501. pubsonline.informs.org/doi/10.1287/mnsc.2021.04150.
12. Association for Accessible Medicines. "Pharmaceutical Shipping Costs Spike in Response to Global COVID-19 Pandemic." Press release. accessiblemeds.org/resources/press-releases/pharmaceutical-shipping-costs-spike-response-global-covid-19-pandemic.
13. U.S. Government Accountability Office. "Drug Shortages: HHS Should Implement a Mechanism to Coordinate Its Activities." GAO-25-107110. April 9, 2025. gao.gov/products/gao-25-107110.
14. U.S. Pharmacopeia. "U.S. Drug Shortages Reach Decade-High and Last Longer." Press release. June 4, 2024. usp.org/news/us-drug-shortages-reach-decade-high-and-last-longer.